Burden of illness of bacterial cellulitis and erysipelas of the leg in the Netherlands

Journal of the European Academy of Dermatology and Venereology

Volumn 20, Issue 7, 2006, Pages 834-839

  Goettsch, W G ^a   Bouwes Bavinck, J N ^c   Hering, R M C ^a,b  

^a PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bacterial cellulitis; Burden of illness; Dermatomycosis; Erysipelas; Lower extremities

Indexed keywords

ANTIDIABETIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CARDIOVASCULAR AGENT; DERMATOLOGICAL AGENT; LINCOSAMIDE; MACROLIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TETRACYCLINE; TRIMETHOPRIM;

ADOLESCENT; ADULT; AGED; ARTICLE; CELLULITIS; CHILD; CONTROLLED STUDY; COST OF ILLNESS; DATA ANALYSIS; DATA BASE; ERYSIPELAS; FEMALE; GENERAL PRACTITIONER; HOSPITAL ADMISSION; HOSPITAL COST; HUMAN; INFANT; INTERNATIONAL CLASSIFICATION OF DISEASES; LEG DISEASE; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PRIORITY JOURNAL; REGISTER; REIMBURSEMENT; SAMPLE (STATISTICS); STANDARDIZATION;

BACTERIAL INFECTIONS; CELLULITIS; ERYSIPELAS; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; INCIDENCE; LEG DERMATOSES; LOWER EXTREMITY; NETHERLANDS; PREVALENCE;

EID: 33746281722     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.01657.x     Document Type: Article

References (17)

1. Swartz MN. Clinical practice. Cellulitis. N Engl J Med 2004; 350: 904-912.
2. Ronnen M, Suster S, Schewach-Millet M, Modan M. Erysipelas. Changing faces. Int J Dermatol 1985; 24: 169-172.
3. Jorup-Ronstrom C. Epidemiological, bacteriological and complicating features of erysipelas. Scand J Infect Dis 1986; 18: 519-524.
4. Chartier C, Grosshans E. Erysipelas. Int J Dermatol 1990; 29: 459-467.
5. Crickx B, Chevron F, Sigal-Nahum M et al. Erysipelas: Epidemiological, clinical and therapeutic data (111 cases) [article in French]. Ann Derm Venereol 1991; 118: 11-16.
6. Roujeau JC, Sigurgeirsson B, Korting HC et al. Chronic dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: A case-control study. Dermatol 2004; 209: 301-307.
7. Mahe E, Toussaint P, Lamarque D et al. Erysipelas in the young population of a military hospital [article in French]. Ann Derm Venereol 1999; 126: 593-599.
8. Dupuy A, Benchikhi H, Roujeau JC et al. Risk factors for erysipelas of the leg (cellulitis): Case-control study. Br Med J 1999; 318: 1591-1594.
9. Herings RM, Bakker A, Stricker BH, Nap G. Pharmaco-morbidity linkage: A feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health 1992; 46: 136-140.
10. Chartier C, Grosshans E. Erysipelas: An update. Int J Dermatol 1996; 35: 779-781.
11. Herings RM, Klungel OH. An epidemiological approach to assess the economic burden of NSAID-induced gastrointestinal events in the Netherlands. Pharmacoeconomics 2001; 19: 655-665.
12. Wiedijk I, Spierings P. Technical brochure: Framework and organisation of the CBV-database. Stichting CBV, Leiden, 1999.
13. Musette P, Benichou J, Noblesse I et al. Determinants of severity for superficial cellulitis (erysipelas) of the leg: A retrospective study. Eur J Int Med 2004; 15: 446-450.
14. Jorup-Ronstrom C, Britton S, Gavlevik A et al. The course, costs and complications of oral versus intravenous penicillin therapy of erysipelas. Infection 1984; 12: 390-394.
15. Sjoblom AC, Eriksson B, Jorup-Ronstrom C et al. Antibiotic prophylaxis in recurrent erysipelas. Infection 1993; 21: 390-393.
16. Corwin P, Toop L, McGeoch G et al. Randomised controlled trial of intravenous antibiotic treatment for cellulitis at home compared with hospital. Br Med J 2005; 330: 129.
17. Eron LJ, Passos S. Early discharge of infected patients through appropriate antibiotic use. Arch Int Med 2001; 161: 61-65.